This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
SOLV Strong Q2 Results Signal Momentum: Is the Stock Worth Buying Now?
by Zacks Equity Research
Solventum beats on Q2 earnings, raises guidance, and powers ahead with transformation despite looming tariff headwinds.
Henry Schein (HSIC) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Henry Schein (HSIC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Henry Schein Stock Falls on Q2 Earnings Miss, Revenues Top
by Zacks Equity Research
HSIC slides after Q2 EPS misses estimates by 6.8%. Revenues beat with 3.2% growth and strength across key segments.
Henry Schein (HSIC) Q2 Earnings Lag Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of -6.78% and +0.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein (HSIC) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
HSIC eyes modest Q2 gains, with dental, medical and specialty segments showing signs of steady momentum.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Henry Schein (HSIC) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Retain Henry Schein Stock in Your Portfolio Right Now?
by Zacks Equity Research
Investors are optimistic about HSIC, owing to the strong Henry Schein One performance. However, macro headwinds and fierce competition pose challenges.
Henry Schein (HSIC) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Henry Schein (HSIC) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Henry Schein (HSIC) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Henry Schein (HSIC) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Henry Schein (HSIC) Up 6.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SOLV's Strong Q1 Signals Turnaround: Is the Stock Worth Betting Now?
by Zacks Equity Research
Solventum beats Q1 estimates, raises guidance, and powers ahead with transformation despite looming tariff headwinds.
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Retain Henry Schein Stock in Your Portfolio Right Now?
by Zacks Equity Research
Investors are optimistic about HSIC, owing to the strong performance of its Henry Schein One business.
Compared to Estimates, Henry Schein (HSIC) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Henry Schein (HSIC) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Henry Schein Q1 Earnings Top Estimates, Revenues Miss, Stock Falls
by Zacks Equity Research
HSIC ends the first quarter of 2025 on a mixed note.
Henry Schein (HSIC) Q1 Earnings Beat Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 3.60% and 1.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Becton Dickinson (BDX) Q2 Earnings Top Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 2.13% and 1.74%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Can Sustained Product Demand Drive CAH Stock Before Q3 Earnings?
by Zacks Equity Research
The continued solid uptake of Cardinal Health's products is expected to have driven fiscal third-quarter revenues despite an uncertain macroeconomic environment.